Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study
暂无分享,去创建一个
Saskia le Cessie | Wendy P J den Elzen | S. le Cessie | A. D. de Craen | W. Assendelft | R. Westendorp | W. de Ruijter | J. Gussekloo | W. D. den Elzen | Willem J J Assendelft | Jacobijn Gussekloo | Rudi G J Westendorp | Anton J M de Craen | Wouter de Ruijter
[1] Leslee J Shaw,et al. Coronary artery calcium to predict all-cause mortality in elderly men and women. , 2008, Journal of the American College of Cardiology.
[2] Anders Larsson,et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. , 2008, The New England journal of medicine.
[3] Li-sheng Liu,et al. Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.
[4] M. Pencina,et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.
[5] P. Macfarlane,et al. The additional value of routine electrocardiograms in cardiovascular risk management of older people , 2008, Scandinavian journal of primary health care.
[6] K. Furie,et al. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.
[7] S. Allender,et al. European cardiovascular disease statistics , 2008 .
[8] Russell Steele,et al. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. , 2008, Journal of the American College of Cardiology.
[9] Douglas G Altman,et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2008, BMJ.
[10] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.
[11] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.
[12] Douglas G Altman,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. , 2014, International journal of surgery.
[13] K. Saag,et al. Quality Indicators for the Care of Osteoarthritis in Vulnerable Elders , 2007, Journal of the American Geriatrics Society.
[14] R. Collins,et al. Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men. , 2007, Archives of internal medicine.
[15] P. Macfarlane,et al. The Routine Electrocardiogram for Cardiovascular Risk Stratification in Old Age: The Leiden 85‐Plus Study , 2007, Journal of the American Geriatrics Society.
[16] A. Zwinderman,et al. Role of the Apolipoprotein BApolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A CaseControl Analysis in EPIC-Norfolk , 2007, Annals of Internal Medicine.
[17] J. Steurer,et al. Prediction of first coronary events with the Framingham score: a systematic review. , 2007, American heart journal.
[18] M. McDermott,et al. The international pandemic of chronic cardiovascular disease. , 2007, JAMA.
[19] K. Alexander,et al. Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence. , 2007, The American journal of geriatric pharmacotherapy.
[20] M. Glickman,et al. Blood Pressure and Survival in the Oldest Old , 2007, Journal of the American Geriatrics Society.
[21] N. Cook. Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.
[22] N. Cook,et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. , 2007, JAMA.
[23] J. Abramson,et al. Are lipid-lowering guidelines evidence-based? , 2007, The Lancet.
[24] D. Levy,et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. , 2006, The New England journal of medicine.
[25] J. Ware. The limitations of risk factors as prognostic tools. , 2006, The New England journal of medicine.
[26] H. Brenner,et al. Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease. , 2006, Archives of internal medicine.
[27] W. Kannel. Cardiovascular disease preventive measures for the older patient: an epidemiologic perspective. , 2006, The American journal of geriatric cardiology.
[28] P. Macfarlane,et al. Abstract 814: CRP and Risk of Vascular Events in PROSPER , 2006 .
[29] Robert A Levine,et al. Geometric Determinants of Functional Tricuspid Regurgitation: Insights From 3-Dimensional Echocardiography , 2006, Circulation.
[30] Eric Boerwinkle,et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. , 2006, Archives of internal medicine.
[31] R. Sulkava,et al. Association Between Blood Pressure and Survival over 9 Years in a General Population Aged 85 and Older , 2006, Journal of the American Geriatrics Society.
[32] Per Magne Ueland,et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. , 2006, The New England journal of medicine.
[33] P. Venge,et al. Troponin I as a Predictor of Coronary Heart Disease and Mortality in 70-Year-Old Men: A Community-Based Cohort Study , 2006, Circulation.
[34] R. Westendorp,et al. In a population-based prospective study, no association between high blood pressure and mortality after age 85 years , 2006, Journal of hypertension.
[35] A. A. Liakishev. [Homocysteine lowering with folic acid and B vitamins in vascular disease]. , 2006, Kardiologiia.
[36] P. Hildebrandt,et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. , 2005, JAMA.
[37] D. Siscovick,et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. , 2005, The New England journal of medicine.
[38] S. Kritchevsky,et al. Inflammatory markers and cardiovascular health in older adults. , 2005, Cardiovascular research.
[39] P. Hildebrandt,et al. N-Terminal Pro-Brain Natriuretic Peptide, C-Reactive Protein, and Urinary Albumin Levels as Predictors of Mortality and Cardiovascular Events in Older Adults , 2005 .
[40] Joël Belmin,et al. Prevention of Cardiovascular Events in Elderly People , 2005, Drugs & aging.
[41] Jing Ma,et al. Inflammatory markers and the risk of coronary heart disease in men and women. , 2004, The New England journal of medicine.
[42] Jan A Kors,et al. Defining unrecognized myocardial infarction: a call for standardized electrocardiographic diagnostic criteria. , 2004, American heart journal.
[43] Vilmundur Gudnason,et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.
[44] L. Chambless,et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. , 2004, JAMA.
[45] Mary T. Roth,et al. Primary Prevention of Coronary Heart Disease in the Elderly , 2003, The Annals of pharmacotherapy.
[46] D. Wald,et al. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis , 2002, BMJ : British Medical Journal.
[47] P. Macfarlane,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.
[48] Per Magne Ueland,et al. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. , 2002, JAMA.
[49] W. Kannel. Coronary heart disease risk factors in the elderly. , 2002, The American journal of geriatric cardiology.
[50] D. Knook,et al. Successful aging in the oldest old: Who can be characterized as successfully aged? , 2001, Archives of internal medicine.
[51] T. Strandberg,et al. C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[52] P. Ridker,et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.
[53] S. Yusuf,et al. Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence , 1999, Annals of Internal Medicine.
[54] D W Bates,et al. Evaluating the appropriateness of digoxin level monitoring. , 1999, Archives of internal medicine.
[55] A. Hoes,et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. , 1999, Archives of internal medicine.
[56] Daniel Levy,et al. Accuracy of Death Certificates for Coding Coronary Heart Disease as the Cause of Death , 1998, Annals of Internal Medicine.
[57] Hendriek C Boshuizen,et al. Blood pressure and mortality in elderly people aged 85 and older: community based study , 1998, BMJ.
[58] S. Vollset,et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. , 1997, The New England journal of medicine.
[59] A. Weverling-Rijnsburger,et al. Total cholesterol and risk of mortality in the oldest old , 1997, The Lancet.
[60] G. Omenn,et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. , 1995, JAMA.
[61] N. Wenger. Coronary Heart Disease at Elderly Age: Determinants of Clinical Decision-Making. , 1995, The American journal of geriatric cardiology.
[62] R. D'Agostino,et al. The Importance of Cardiovascular Risk Factors in the Elderly. , 1995, The American journal of geriatric cardiology.
[63] G. Murphy,et al. Monitoring quality improvements and measuring results. , 1995, Q.A. brief.
[64] C. Mulrow,et al. Hypertension in the elderly. Implications and generalizability of randomized trials. , 1994, JAMA.
[65] K. Anderson,et al. Cardiovascular disease risk profiles. , 1991, American heart journal.
[66] K. Anderson,et al. An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.
[67] J. C. van Houwelingen,et al. Predictive value of statistical models , 1990 .
[68] S. le Cessie,et al. Predictive value of statistical models. , 1990, Statistics in medicine.
[69] G. Bettelli,et al. [Isolated systolic hypertension in the elderly]. , 1989, Medicina.
[70] R. Gillum,et al. Coronary heart disease in the elderly. , 1988, Comprehensive therapy.
[71] Ronald J. Prineas,et al. The Minnesota code manual of electrocardiographic findings : standards and procedures for measurement and classification , 1982 .
[72] A. Dyer,et al. Hypertension in the elderly. , 1977, The Medical clinics of North America.
[73] A. Belanger,et al. The Framingham study. , 1976, British medical journal.
[74] K. Mccully. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. , 1969, The American journal of pathology.
[75] W. Kannel,et al. The Framingham study: a prospective study of coronary heart disease. , 1962, Federation proceedings.
[76] W. Kannel,et al. Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. , 1961, Annals of internal medicine.